UK novel RNA therapeutics firm Silence Therapeutics will receive a milestone payment of $2 million from Mallinckrodt, after work started on a third target being explored under an ongoing collaboration. 26 February 2021
Oneness Biotech has received approval from Taiwan Ministry of Health and Welfare for the New Drug Application (NDA) for its plant-based topical cream ON101 to treat diabetic foot ulcers. 25 February 2021
Norwegian biopharma Nordic Nanovector, a company seeking to become a leader in the development of targeted therapies for hematological cancers, has raised approximately 361 million Norwegian krone ($42.5 million) through a private placement. 24 February 2021
USA-based Catalent is to acquire Delphi Genetics, a plasmid DNA (pDNA) cell and gene therapy contract development and manufacturing organization (CDMO) from Belgium. 23 February 2021
Fast-growing Danish biotech Genmab has appointed Tahamtan Ahmadi to the newly-created position of executive vice president and chief medical officer, head of experimental medicines. 22 February 2021
Germany’s BioNTech and partner Pfizer said on Friday they had submitted new data to the US Food and Drug Administration demonstrating the stability of their COVID-19 vaccine when stored at -25°C to -15°C (-13°F to 5°F), temperatures more commonly found in pharmaceutical freezers and refrigerators. 20 February 2021
The developers of Comirnaty, the first approved vaccine against COVID-19, have kicked off a global Phase II/III trial to test the product in pregnant women. 19 February 2021
Israeli biotech RedHill Biopharma today announced agreements with Switzerland-based Cosmo Pharmaceuticals to manufacture two key products; RedHill’s largest selling product in the USA, Movantik (naloxegol) and RHB-204, currently in a Phase III US study as a stand-alone, first-line orally-administered treatment for pulmonary nontuberculous mycobacteria (NTM) disease. 18 February 2021
With a number of national regulators declaring they would not approve COVID-19 Vaccine AstraZeneca for older age group because of questions in its efficacy in such populations, there was good news for the UK’s AstraZeneca and Oxford University, with the much-anticipated decision from the World Health Organization. 10 February 2021
Canada’s Zymeworks has expanded its commercial team, promoting former senior VP of commercial James Priour to the role of chief commercial officer. 10 February 2021
Chengdu, China-based Anticancer Bioscience (ACB), a pioneer in synthetic lethal approaches to precision oncology, announced today that, having successfully closed an additional financing round, raising 63 renminbi (~$10 million), it has already achieved positive animal data in its small molecule program targeting MYC overexpression. 8 February 2021
Germany’s Merck has agreed to significantly increase production of urgently needed lipids for BioNTech and Pfizer’s COVID-19 vaccine, Comirnaty. 5 February 2021
Keytruda (pembrolizumab) has become the first immunotherapy in combination with pemetrexed and chemotherapy to be recommended by the National Institute for Health and Care Excellence (NICE) for routine commissioning. 4 February 2021
Shares in Vaxart have fallen sharply, after the firm released mixed data from a Phase I study of COVID-19 vaccine candidate VXA-CoV2-1. 4 February 2021
Japanese drugmaker Chugai Pharmaceuticals today announced that, based on the recommendation of the Appointment Committee, the company resolved to appoint Osamu Okuda, currently representative director, president and chief operating officer, as chief executive as of March 23, 2021. 4 February 2021
The European regulator has released a safety update on BioNTech and Pfizer’s COVID-19 vaccine, Comirnaty, concluding that real-world data from vaccinations is consistent with the known safety profile of the vaccine, with no new side effects to report. 29 January 2021
The Serum Institute of India (SII), the world's biggest vaccine maker, has applied to authorities to conduct a small domestic trial of Novavax’ COVID-19 vaccine, NVX-CoV2373, which was found to be 89.3% effective in a UK trial. 29 January 2021
Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to expand its portfolio of marketed rare disease medicines. 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Bristol Myers Squibb has received a new approval from the US Food and Drug Administration for its blockbuster checkpoint blocker, Opdivo (nivolumab). 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
The US Food and Drug Administration (FDA) has granted the Gilead Sciences subsidiary Kite a Regenerative Medicine Advanced Therapy Designation (RMAT) for Yescarta (axicabtagene ciloleucel) for adults with newly-diagnosed, high-risk large B-cell lymphoma (LBCL). 3 October 2024
Kedrion Biopharma has finalized an agreement with Germany-based Biotest for the long-term commercialization and distribution of Yimmugo (immune globulin) in the USA. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Privately-held Ferring Pharmaceuticals has announced the opening of a global manufacturing hub in Finland for the drug substance of its intravesical non-replicating gene therapy Adstiladrin (nadofaragene firadenovec-vncg). 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
The BioIndustry Association (BIA), in collaboration with the Centre for Process Innovation (CPI), has published a new report on the UK’s mRNA sector. 2 October 2024
Aspen Neuroscience, a private biotechnology company specializing in autologous cell therapies, has announced the opening of a major new facility near its headquarters in San Diego. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024